Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 with Chemoradiotherapy in Recurrent or Metastatic ESCC
NCT03927495Phase 2Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- May 2019
- Primary completion
- Jun 2021
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of erfonrilimab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoints: Dose-limiting toxicity at 28 days, Progression Free Survival Rate at 6 months and 1 more. Status: unknown.
02
Drugs
erfonrilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03927495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927495.